. Agen-ce-nationale, Accrédit ation et d ' Evaluation en Sa nté, pp.1-10

C. Pallaud and R. Guegu-en, Genetic influences on lip id metabolism trait variability within the Stanislas Cohort, J Lip id Res, vol.1, issue.11, pp.42-1879

Y. Guo and D. C. Jami-son, The distribution of SNPs in human gene regulatory regions, BMC Genomics, issue.6, p.140, 2005.

C. Ng, S. , and M. A. Grow, A multilocus genotyping assay for candidate markers of cardiovascular disease risk, Genome Res, issue.9 10, pp.936-985, 1999.

C. Hoppe and S. Cheng, A novel multilocus genotyp ing assay to identify genetic predictors ofstroke in sic/de cell anaemia, Br J Haematol, vol.1, issue.114 3, pp.718-738

C. Hoppe and W. Klit-z, Gene interactions and stroke risk in chi/dren with sic/de cell anemia, Blood, vol.103, issue.9, pp.1-6, 2004.

C. Pallaud and C. Sass, APOC3, CETP, jibrinogen, and MTHFR are genetic determinants of carotid intima-media thickness in healthy men (the Stanislas cohort)

S. Maumus and B. Ma, Analysis of the efJect of multiple genetic variants of cardiovascular disease risk on insulin concentration variability in healthy adults of the STANISLAS cohort. The role of FGB-455 GIA polymorphism, Atherosclerosis, vol.1, issue.2, pp.369-76, 2007.

H. Berrahmoune and B. Herb, Association between TNF and IL-I bloc polym orphisms and plasma MCP-I concentration. Atheroscle ros is, pp.348-53, 2007.
DOI : 10.1016/j.atherosclerosis.2006.05.015

I. Ch-eng, S. , and C. , A multilocus genotyping assay for cardiovasc ular disease, Clin Chem Lab Med, vol.8, issue.368, pp.56-57

G. Barlo-vatz-meimon and M. Adolphe, Cultures de cellules animales, Méthodologies -App lications. Techniques en, 2003.

K. Bohnet and A. Regis-bailly, Ap olip oprotein E genotype epsilon 4leps i/on 2 in the STANISLAS Cohort Study--domin ance of the eps ilon 2 alle, Ann Hum Genet, pp.60-509, 1996.

F. Brahimi and P. Bertr, Control of ap olipoprotein E secretion in the human hep atoma cell line KYN-2, Cell Biochem Funct, vol.1, issue.191, pp.5-6

1. Auwerx, The human leukemia cell line, THP-I : a multifacetted model for the study of monocyt e-macrophage difJerentiation. Experie ntia, pp.22-25, 1991.

T. Ma-ejima and H. , EfJect of pitavastatin on apolipoprotein A-I production in HepG2 cell, Bio ch em Biophys Res Commun, vol.24, issue.32, pp.835-844, 2004.

C. F. Vogel and E. Sciullo, Indu ction ofpro inflam matory cytokines and C-reactive protein in human macrophage cell line U937 exposed to air pollution particulates

E. F. Brandon and T. M. Bosch, Validation of in vitro cell models used in drug metabolism and transport studies; genotyp ing of cytochrome P450, phase II enzymes and drug transporter polym orphism s in the human hepatom a (HepG2

Y. H. Hamid and C. S. Rose, Variations of the interleukin-6 promoter are associated with features of the metabolic syndrome in Caucasian Danes, Diabetologia, vol.52, issue.2, pp.251-60, 2005.
DOI : 10.1007/s00125-004-1623-0

R. Y. Zee and N. R. Cook, Threonine for alanine substitution in the eotaxin (CCLI1) ge ne and the risk of incident myo cardial infarction. Atherosclero sis, pp.91-95, 2004.

I. Sbarsi, C. Fa, and !. Cone, Inflammation and Atherosclerosis: The Role of TNF and TNF Receptors Polymorphisms in Coronary Artery Disease, International Journal of Immunopathology and Pharmacology, vol.91, issue.1, pp.145-54, 2007.
DOI : 10.1136/bmj.316.7139.1236

M. Fernandez-arquero and R. Arroyo, Primary association of a TNF gene polymorphism with susceptibility to multiple sclerosis, Neurology, vol.53, issue.6, pp.1361-1364, 1999.
DOI : 10.1212/WNL.53.6.1361

A. Ponthieux and D. Lambert, Association between Gly 241Arg ICAM-I gene polymorphism and serum sICAM-I con centration in the Stanislas cohort Association of intercellular adh esion molecule-I gene with type 1 diab etes, Eur J Hum Genet Lancet, issue.9397, pp.36-38, 2003.

S. Penco and E. Grossi, Assessme nt of the rol e ofge netic polymorphism in venous thrombosis through artificial neural networks, Ann Hum Genet, pp.69-693, 2005.

T. Djuric and M. Zivkovic, Endothelial NOS G894 T and MMP-3 5A/6A gene polymorphisms and hypertension in Serbian population, Journal of Clinical Laboratory Analysis, vol.13, issue.6, pp.241-247, 2005.
DOI : 10.1161/01.CIR.98.6.535

J. Auer and T. Weber, Genetic Polymorphisms in Cytokine and Adhesion Molecule Genes in Coronary Artery Disease, American Journal of PharmacoGenomics, vol.95, issue.18, pp.317-345, 2003.
DOI : 10.2165/00129785-200303050-00003

A. Testa and F. A. Benedetto, The E-selectin gene polymorphism and carotid atherosclerosis in end-stage renal disease, Nephrology Dialysis Transplantation, vol.21, issue.7, pp.1921-1927, 2006.
DOI : 10.1159/000081870

K. Wenzel and M. Ernst, DNA polymorphisms in adh esion molecule ge nes--a new riskfactor for early ath erosclerosis, Hum Genet, vol.97, issue.1, pp.15-20, 1996.

K. A. Volcik and C. M. Ballantyne, Specifie P-selectin and Psselectin glycoprotein lig and-I genotypes/haplotypes are associated with risk ofincident CHD and ischemie stroke: The Atherosclerosis Risk in Communities (ARlC) study, Atherosclerosis, p.67, 2007.

. Grainger-heathcote, Genetic control of the circulating concentration of transforming growth factor type beta1, Human Molecular Genetics, vol.8, issue.1, pp.93-100, 1999.
DOI : 10.1093/hmg/8.1.93

M. P. Sie and A. Uitterlinden, TGF-beta 1 polymorphisms and risk ofmyocardial infarction and stroke: the Rotterdam Study, Stroke, issue.11, pp.37-2667, 2006.
DOI : 10.1161/01.str.0000244779.30070.1a

URL : http://stroke.ahajournals.org/content/strokeaha/37/11/2667.full.pdf

A. Csaszar and J. Duba, Increased freq uency of the C3*F allele and the Leiden mutation of coag ulation factor V in patients with severe coronary heart dis eas e who survived myo cardial infarction, Exp Clin Immunogenet, vol.1, issue.184, pp.206-218

E. Bernardo and . Angiolillo, Influ ence of the CD14 C260T promoter polymorphism on C-reactive protein levels in patients with coronary art ery dis ease

R. Giacconi and C. Caruso, CD14 C (-260)T polymorphism, atherosclerosis, elderly: Role of cytokines and metallothioneins, International Journal of Cardiology, vol.120, issue.1, pp.45-51, 2006.
DOI : 10.1016/j.ijcard.2006.08.035

X. B. Wang and X. Zhao, A CTLA-4 gene polymorphism at position ???318 in the promoter region affects the expression of protein, Genes & Immunity, vol.6, issue.4, pp.233-237, 2002.
DOI : 10.1046/j.1468-1331.1999.640491.x

Y. Kokubo and H. Tomoike, Association of sixty-one non-synonymous polymorphisms in forty-one hypertension candidate ge nes with blood pressure variation and hypertension, Hyp ertens Res, issue.8, pp.29-611, 2006.

J. L. Benton and J. Ding, Associations between two common polymorphisms in the ABCA1 gene and subclinical atherosclerosis: Multi-Ethnic Study of Atherosclerosis (MESA), Atherosclerosis, vol.193, issue.2, pp.352-60, 2007.
DOI : 10.1016/j.atherosclerosis.2006.06.024

M. K. Jensen and J. K. Pai, Common ge netic variation in the A TP-binding casse tte transporter A 1, plasma lip ids, and risk of coronary hear t disease ln-depth haplotype analysis of ABCA 1 ge ne polymorphisms in relation to plasma Ap oA l levels and myocardial infarction, Atherosclerosis, vol.24, issue.4, pp.775-81, 2004.

J. A. Hubacek and K. E. Berge, Polymorphisms in ABCG5 and AB CG8 transporters and p lasma cholesterol levels, Physiol Res, vol.53, issue.4, pp.395-435, 2004.

E. Viturro and M. De-oya, Cholesterol and saturated fat intake determine the effect of polymorphisms at ABCG5/ABCG8 genes on lipid levels in children, Genetics in Medicine, vol.40, issue.9, pp.594-603, 2006.
DOI : 10.1111/j.1651-2227.2002.tb00096.x

G. D. Leschziner and T. Andrew, ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research, The Pharmacogenomics Journal, vol.14, issue.3, pp.154-79, 2007.
DOI : 10.1038/sj.ejhg.5201583

E. L. Woodahl and Z. Yan, Multidrug resistance ge ne G1l99A polymorphism alters effl ux transport activity ofP-glycoprotein Pharmacogenetic scree ning of CYP3A and ABCB l in relation to population pharmacokinetics of docetaxel, J Pharmacol Exp Ther Clin Cancer Res, vol.10, issue.82, pp.1199-207, 2004.

Q. Xing and R. Gao, gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients, Pharmacogenomics, vol.783, issue.7, pp.987-93, 2006.
DOI : 10.1023/A:1012244520615

C. Marzolini and E. Paus, Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance, Clinical Pharmacology & Therapeutics, vol.75, issue.1, pp.13-33, 2004.
DOI : 10.1016/j.clpt.2003.09.012

C. Q. Lai and L. D. , The APOA1/C3/A4/A5 gene cluster, lipid metabolism and cardiovascular disease risk, Current Opinion in Lipidology, vol.16, issue.2, pp.153-66, 2005.
DOI : 10.1097/01.mol.0000162320.54795.68

O. Olivieri and C. Stran, ApoC-IIl ge ne polymorphisms and risk of coronary artery disease, J Lipid Res, issue.9, pp.43-1450, 2002.

C. F. Xu and P. Talmud, Association between ge netic varia tion at the APO AI-CIlI- AIV ge ne cluster and familial combined hyperlipidaemia, Clin Genet, issue.6, pp.46-385, 1994.
DOI : 10.1111/j.1399-0004.1994.tb04404.x

N. Barzilai and G. Atzmon, Uniqu e lip oprotein ph enotype and ge notype associated with excep tional longevity, Jama, issue.15, pp.290-2030, 2003.

J. F. Thom-pson and M. E. Lira, Po lymorphisms in the CETP ge ne and association with CETP mass and HDL levels. Ath erosclerosis, pp.195-204, 2003.

R. V. Andersen and H. H. Wittrup, Hepatic lipase mutations.elevated high -density lipoprotein cholesterol, and increased risk ofischemie heart disease: the Copenhage n City Heart Study, J Am Coll Cardiol, issue.11, pp.41-1972, 2003.

X. Guo and S. Cheng, Hypertension ge nes are ge netic markers f or insulin sensitivity and resistan ce GLU-27 variant of beta 2-adrenergic receptor po lymorphisms is an independent risk factor for coronary ath erosclerotic disease Atheros clerosis, Hypertension, vol.45, issue.4, 2005.

A. A. Se-thi and A. Ty-bjaerg-hansen, 164Jle al/ele in the beta2-Adrenergic receptor gene is associated with risk of elevated blood pressure in women. The Copenhagen City Heart Study, Pharmacogenet Genomics, issue.9, pp.15-633, 2005.

G. Iaccarino and R. Izzo, ??2-Adrenergic receptor polymorphisms and treatment-induced regression of left ventricular hypertrophy in hypertension, Clinical Pharmacology & Therapeutics, vol.80, issue.6, pp.633-678, 2006.
DOI : 10.1016/j.clpt.2006.09.006

K. Leinewe-ber and G. Tend-eri-ch, Is there a role of the Thr164Ile-??2-adrenoceptor polymorphism for the outcome of chronic heart failure?, Basic Research in Cardiology, vol.93, issue.6, pp.479-84, 2006.
DOI : 10.1152/ajpheart.00324.2003

S. V. Vormfelde and D. Se-hrt, Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the efJects of loop diuretic drugs Linkage and association with the N OS2A locus on chromosome l 7qIl in multiple sclerosis, Clin Pharm acol Ther Ann Neurol, vol.82, issue.36, pp.55-79, 2004.

T. D. Howard and W. H. Gil, Promoter polymorphisms in the nitric oxide syn thase 3 gene are associated with ischemie stroke susceptibility in yo ung black women. Stro ke, pp.1848-51, 2005.

K. Berger and F. Stogbauer, The glu298asp polymorphism in the nitric oxide synthase 3 gene is associated with the risk of ischemic stroke in two large independent case???control studies, Human Genetics, vol.13, issue.2, pp.169-78, 2007.
DOI : 10.1212/01.WNL.0000147542.37657.2F

G. V. Dedoussis and S. Maumus, Natriuretic peptide Val7Met substitution and risk of coronary artery disease in Greek patients with familial hypercholesterolemia, Journal of Clinical Laboratory Analysis, vol.5, issue.3, pp.98-104, 2006.
DOI : 10.1161/01.HYP.37.6.1416

E. Pongracz and H. Andrikovies, Contribution of the -455G/A polymorphism at beta-fibrinogen gene and of the Leiden mutation to hemorh eological parameters in ischemie stro ke patients. Clin Hemorheo l Microe ire, pp.75-82, 2006.

S. Ka-thiresan and Q. Ya-ng, Common ge netic variation in five thrombosis genes and relations to plasma hemostatic protein level and cardiovascular disease risk, Arterios cler Th romb Vase Biol, vol.26, issue.6, pp.140-145, 2006.

S. M. Boekholdt and N. R. Bijsterveld, Genetic variation in coag ulation and fibrinolytic pro teins and their relation with acute myocardial infarction: a sys tematic review, Circulation, vol.1, issue.10425, pp.3063-3071

P. E. Morange and N. Saut, Association ofPlasminog en Activator Inhibitor (PA!)-l (SERFINE1) SNPs with My oca rdial Infa rction , Plasm a PAl-l, and Metabolic Parameters. The HlFME CH Study, 2007.

J. A. No-ble and A. White, A polymorphism in the TCF 7 gene, C883A, is assoc iated with type 1 diabetes. Di ab etes, pp.52-1579, 2003.

M. J. Tavema and J. L. Selam, Association between a pro tein po ly morphism in the start codon of the vitamin D receptor ge ne and severe diabetic retinopathy in Cp eptide-negative type 1 diabetes, J Clin Endoerinol Metab, issue.8, pp.90-138, 2005.

J. C. On-gagna and M. Pinget, Vitamin D'-binding pro tein g ene polymorphism association with IA-2 autoantibodies in type 1 diab etes, Clin Bio ehem, vol.38, issue.4, pp.15-24, 2005.

K. L. Klo-s and C. F. Sin, Consistent efJects ofgenes involved in reverse cholesterol transport on p lasma lipid and apo lipoprotein levels in CARDIA participants, Arterioscler Thro mb Vase Biol, issue.8, pp.26-1828, 2006.

H. Kno-blaueh and . Bau-erfeind, Haplotyp es and SNPs in 13 lipid-relevant ge nes exp lain most of the genetic variance in high -density lipoprotein and low-density lipoprotein cholesterol, Hum Mol Genet, issue.10, pp.13-993, 2004.

C. Posada, Pharma cogenetic study of statin therapy and cholesterol reduction, Jama, vol.1, issue.1 2923, pp.282-283, 2004.

. Ill, G. Schmitz, and T. Langmann, Pharmacogenomics of cholesterol-lowering therapy, Vascul Phannacol, vol.44, issue.2, pp.75-89, 2006.

J. F. Thompson and M. Man, An association study of 43 SNPs in 16 candidate genes with atorvastatin response, The Pharmacogenomics Journal, vol.75, issue.6, pp.352-360, 2005.
DOI : 10.1016/j.clpt.2003.12.016

M. Fiegenbaum and F. R. Da-silveira, The l'ole of common variants of ABCBl , CYP3A4, and CYP3A5 genes in lipi d-lowering efficacy and safety of simvastatin treatment, Clin Phannacol Th er, vol.5, issue.78 5, pp.55-56

A. H. Maitland-van-der-zee and B. H. Stricker, Adherence to and dosing of betahydroxy-beta-methylgluta ryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-gen0 types, Phannacogenetics, vol.13, issue.2, pp.19-23, 2003.

E. Coroneos and E. Sim, Arylamine N-acetyltransferase activity in human cultured celilines, Biochem J, issue.2, pp.294-342, 1993.

F. Namour and J. Olivi-er, Transcobalamin codon 259 polymorphism in HT-29 and Caco-Z celis and in Caucasians: relation to transcobalamin and homocysteine concentration in blood, Blood, vol.1, issue.974, pp.1092-1100

J. Sun and H. Huang, Study on the expression and mutation of human telomeric repeat binding fac tor (hTRF1) in 10 malignant hematopo ietic cell lines, J Zhejiang Univ Sei B, issue.612, pp.1141-1148, 2005.

K. B. Bouker and T. C. Skaar, The A4396G polymorphism in interferon regulatory factor 1 is frequently expressed in breast cancer cell lines, Cancer Genetics and Cytogenetics, vol.175, issue.1, pp.61-65, 2007.
DOI : 10.1016/j.cancergencyto.2006.12.008

M. A. Rum-i and H. Sato, Peroxisom e pro liferator-activated receptor gamma ligand-induced growth inhibition of human hepatoceliular carcinoma, Br J Cancer, vol.1, issue.841 2, pp.1640-1647

L. Yu and J. , Identification and expression of novel isoforms of human stromal cell-derived factor 1, Gene, vol.374, pp.174-183, 2006.
DOI : 10.1016/j.gene.2006.02.001

B. Coll and C. Alonso-villaverd-e, The stromal derived fa ctor-l mutated allele (SDF1-3'A) is associated with a lower incidence of atherosclerosis in HIV-inf ected pa tients, Aids, issue.16, pp.19-1877, 2005.

N. Shijubo and . Kawabata, Clinical aspects of Clara cell I O-kDa prot ein/ uteroglobin (secretoglobin l AI). CUIT Phann Des, pp.1139-1188, 2003.

K. E. Berge and H. Tian, Accumulation of Dietary Cholesterol in Sitosterolemia Caused by Mutations in Adjacent ABC Transporters, Science, vol.290, issue.5497, pp.290-1771, 2000.
DOI : 10.1126/science.290.5497.1771

L. Zine-h and A. L. Beitelshees, Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hyp ertension. Clin Phannacol Th er, pp.536-580, 2004.